

THE LAST DAY FOR TRADING WITH WARRANTS OF SERIES TO1 IN EMPICURE IS TODAY, MAY 11, 2022

Today, 11 May 2022, is the last day for trading with warrants of series TO1 in Emplicure AB (publ) (“Emplicure” or the “Company”). The subscription period runs up to and including 13 May 2022. Each warrant of series TO1 entitles the holder to subscribe for one (1) new share in the Company at a price of SEK 2.09 per share.

Note that warrants that are not exercised on 13 May 2022 at the latest or are sold on 11 May 2022 at the last, will expire without value. To ensure that warrants of series TO1 do not expire without value, the holder of such warrants must exercise such warrants for subscription of new shares or sell such warrants.

Summarized terms for warrants of series TO1:

Last day of exercise of TO1 for subscription of shares: 13 May 2022.

Subscription price: SEK 2.09 per share.

Volume: 9,600,000 warrants of series TO1. If all warrants of series TO1 are exercised, the number of shares in the Company will increase with 9,600,00 shares, and the Company will receive approximately SEK 20.1 million before issuing costs.

Last day for trading with warrants of series TO1: 11 May 2022.

How to exercise warrants of series TO1:

Nominee-registered warrants (Custody account)

Subscription and payment for shares subscribed for through exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.

Direct-registered warrants (Securities account)

No accounts for issuing nor any instructions regarding payments will be sent out. Subscription of shares shall be made through simultaneous payment in accordance with the instructions on the application form. The warrants will thereafter be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.

Application form including payment instructions is available at the Company’s website, www.emplicure.com and on Mangold Fondkommission AB’s website www.mangold.se.

Advisors

Mangold Fondkommission AB is the financial advisor and issuing agent and Advokatfirman Lindahl KB is the legal advisor to Emplicure in connection with the exercise of the warrants.



Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subsidiary, Amplicon AB develops consumer products, with dry white oral nicotine as the first product. Read more at www.emplicure.com

For more information, please contact:

Torbjörn W. Larsson

CEO, Emplicure

Telephone: +46 707 476 599

E-mail: torbjorn.walkerlarsson@emplicure.com

Erik Magnusson

CFO & Investor Relations, Emplicure

Telephone: +46 708 565 245

E-mail: erik.magnusson@emplicure.com



Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subsidiary, Amplicon AB develops consumer products, with dry white oral nicotine as the first product. Read more at www.emplicure.com